Wells Fargo’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-250
| Closed | – | – | 6918 |
|
|
2018
Q3 | $0 | Hold |
250
| – | – | ﹤0.01% | 6834 |
|
|
2018
Q2 | $0 | Hold |
250
| – | – | ﹤0.01% | 6878 |
|
|
2018
Q1 | $0 | Hold |
250
| – | – | ﹤0.01% | 6815 |
|
|
2017
Q4 | $0 | Hold |
250
| – | – | ﹤0.01% | 6800 |
|
|
2017
Q3 | $0 | Hold |
250
| – | – | ﹤0.01% | 6726 |
|
|
2017
Q2 | $0 | Hold |
250
| – | – | ﹤0.01% | 6760 |
|
|
2017
Q1 | $0 | Hold |
250
| – | – | ﹤0.01% | 6787 |
|
|
2016
Q4 | $0 | Buy |
250
+125
| +100% | +$396 | ﹤0.01% | 6728 |
|
|
2016
Q3 | $1K | Sell |
125
-375
| -75% | -$2.41K | ﹤0.01% | 6155 |
|
|
2016
Q2 | $5K | Buy |
500
+250
| +100% | +$2.57K | ﹤0.01% | 5838 |
|
|
2016
Q1 | $3K | Buy |
+250
| New | +$2.81K | ﹤0.01% | 6008 |
|
|
2014
Q4 | – | Sell |
-100
| Closed | -$4K | – | 6779 |
|
|
2014
Q3 | $4K | Hold |
100
| – | – | ﹤0.01% | 5906 |
|
|
2014
Q2 | $4K | Hold |
100
| – | – | ﹤0.01% | 5873 |
|
|
2014
Q1 | $5K | Sell |
100
-63
| -39% | -$3.08K | ﹤0.01% | 5574 |
|
|
2013
Q4 | $6K | Buy |
163
+113
| +226% | +$10.7K | ﹤0.01% | 5340 |
|
|
2013
Q3 | $5K | Hold |
50
| – | – | ﹤0.01% | 5315 |
|
|
2013
Q2 | $4K | Buy |
+50
| New | +$4.79K | ﹤0.01% | 5285 |
|
Other funds holding IMUC
Wells Fargo's IMUC Position: Q4 2018 in Review
Wells Fargo sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 250 shares.
Wells Fargo first reported a position in IMUC in Q2 2013 and held it in 17 quarters. The position peaked at $6K in Q4 2013. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.
- Wells Fargo reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
- Wells Fargo sold 250 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018.
- Wells Fargo first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 17 quarters.
- Wells Fargo's ImmunoCellular Therapeutics, Ltd. position peaked at $6K in Q4 2013.
- 3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.
Based on Wells Fargo's 13F filing for Q4 2018, filed 11 Feb 2019.